Category News

OCB appoints James Otter as new CEO

James Otter

Oxford, UK, 15th July 2019:    Oxford Cancer Biomarkers has appointed James Otter as Chief Executive Officer. This represents a key growth milestone for the company which aims to benefit cancer patients through the implementation of advanced precision oncology diagnostics to improve…

PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership

Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP). This investment marks an exciting new commercial phase for the Oxford university spin-out as the company translates innovative cancer biomarker…